EudraCT Number: 2020-000949-14 Sponsor Protocol Number: VIB0551.P3.S1 Start Date: 2020-11-16
Sponsor Name: Viela Bio, Inc.
Full Title: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF INEBILIZUMAB IN ADULTS WITH MYASTHENIA GRAVIS
Medical condition: Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).
Disease: Version SOC Term Classification Code Term Level
21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2019-002625-29 Sponsor Protocol Number: GWSP19066 Start Date: 2020-01-14
Sponsor Name: GW Pharma Limited
Full Title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis
Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS)
Disease: Version SOC Term Classification Code Term Level
20.0 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: PL (Ongoing) GB (Ongoing)
Trial results: (No results available)
EudraCT Number: 2017-004783-35 Sponsor Protocol Number: OPH2005 Start Date: 2018-07-10
Sponsor Name: IVERIC bio
Full Title: A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease
Medical condition: Autosomal Recessive Stargardt Disease
Disease: Version SOC Term Classification Code Term Level
20.1 10010331 - Congenital, familial and genetic disorders 10062766 Stargardt's disease PT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Ongoing) GB (Ongoing) HU (Completed) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-001243-15 Sponsor Protocol Number: S63874 Start Date: 2020-03-26
Sponsor Name: UZLeuven
Full Title: Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.
Medical condition: COVID-19
Disease: Version SOC Term Classification Code Term Level
20.0 100000004862 10038700 Respiratory infection LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BE (Completed)
Trial results: View results
EudraCT Number: 2020-000496-20 Sponsor Protocol Number: INCMGA0012-204 Start Date: 2020-12-14
Sponsor Name: Incyte Corporation
Full Title: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemothe...
Medical condition: Endometrial cancer
Disease: Version SOC Term Classification Code Term Level
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: FR (Ongoing) GR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-000873-26 Sponsor Protocol Number: CLXH254C12201 Start Date: 2020-10-14
Sponsor Name: Novartis Pharma AG
Full Title: A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV6...
Medical condition: previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: NO (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) NL (Ongoing) BE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-001984-10 Sponsor Protocol Number: WO42312 Start Date: 2020-12-23
Sponsor Name: F. Hoffmann-La Roche Ltd
Full Title: A PHASE II, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMPARED WITH PHYSICIAN'S CHOICE OF ENDOCRINE MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED ES...
Medical condition: Estrogen receptor (ER)-positive, HER2 negative locally advanced or metastatic breast cancer who have received one or two prior lines of systemic therapy in the locally advanced (recurrent or progre...
Disease: Version SOC Term Classification Code Term Level
23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2019-003982-17 Sponsor Protocol Number: SGN35-015 Start Date: 2020-10-21
Sponsor Name: SEATTLE GENETICS, INC.
Full Title: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant...
Medical condition: • Hodgkin lymphoma (HL) • CD30-expressing peripheral T-cell lymphoma (PTCL)
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001412 Adult T-cell leukemia-lymphoma LLT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065855 Extranodal NK/T-cell lymphoma, nasal type LLT
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073481 Enteropathy-associated T-cell lymphoma PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022703 Intestinal T-cell lymphoma LLT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061232 Lymphoproliferative disorder PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066957 Hepatosplenic T-cell lymphoma PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2019-002455-42 Sponsor Protocol Number: WO41554 Start Date: 2020-08-27
Sponsor Name: F. Hoffmann-La Roche Ltd
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PA...
Medical condition: Breast cancer
Disease: Version SOC Term Classification Code Term Level
20.0 100000004864 10027475 Metastatic breast cancer LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) BE (Ongoing) PT (Ongoing) GB (GB - no longer in EU/EEA) DK (Ongoing) HU (Ongoing) PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2017-000597-11 Sponsor Protocol Number: CA022-001 Start Date: 2018-07-27
Sponsor Name: Bristol-Myers Squibb International Corporation
Full Title: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.
Medical condition: Advanced Solid Tumors
Disease: Version SOC Term Classification Code Term Level
20.0 100000004864 10065252 Solid tumor LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) DE (Ongoing) PL (Ongoing) FI (Ongoing)
Trial results: (No results available)
Medical Conditions
Sponsors and Collaborators
Drug Interventions